Form 8-K - Current report:
SEC Accession No. 0001193125-22-175557
Filing Date
2022-06-16
Accepted
2022-06-16 16:36:10
Documents
12
Period of Report
2022-06-16
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d320447d8k.htm   iXBRL 8-K 35327
  Complete submission text file 0001193125-22-175557.txt   160935

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA clvs-20220616.xsd EX-101.SCH 2879
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE clvs-20220616_lab.xml EX-101.LAB 17996
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE clvs-20220616_pre.xml EX-101.PRE 11277
6 EXTRACTED XBRL INSTANCE DOCUMENT d320447d8k_htm.xml XML 3355
Mailing Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301
Business Address 5500 FLATIRON PARKWAY SUITE 100 BOULDER CO 80301 (303) 625-5000
Clovis Oncology, Inc. (Filer) CIK: 0001466301 (see all company filings)

EIN.: 900475355 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35347 | Film No.: 221021080
SIC: 2834 Pharmaceutical Preparations